Synthesis and biological evaluation of nicotinic acid derivatives as anti-hyperlipidemic potential in animal model

Muhammad Kifayatullah; Sudhair Abbas; Sadaf Wadood; Kamran Ahmad Chishti; Irnum Ambreen; Nisar Zamin Shah; Haroon Badshah

Synthesis and biological evaluation of nicotinic acid derivatives as anti-hyperlipidemic potential in animal model

Abstract

Present research was designed to synthesize derivatives of nicotinic acid and to evaluate their effect against hyperlipidemic animal model. Derivatives of nicotinic acid were synthesized and characterized by UV, IR and 1 H-NMR techniques. Furthermore, these compounds were screened for anti-hyperlipidemic activity in male healthy rabbits divided into five groups. Each group containing five animals. Group I received only high cholesterol diet (150 days) and was named as untreated. While, group II-V received the high cholesterol diets from day 0 – 120 days followed by synthesized nicotinic acid derivatives, nicotinic acid and bezafibrate separately at dose (30 mg/day and 50 mg/day) intravenously. It was found that nicotinic acid derivatives receiving animals produced significant (p<0.01) anti- hyperlipidemic effect as compared to untreated group. The highest effect was shown by derivative II producing matchable results in lowering of all the lipid profile parameters. Hypolipidemic effect produced by derivative II was even better than nicotinic acid and bezafibrate. Furthermore, bezafibrate effect for lowering the low-density lipoprotein serum levels were found slight significant (p<0.05), while no significant p>0.05 in lowering total cholesterols and increasing HDL level. Present works established the significant hypolipidemic potential of newly synthesized nicotinic acid derivatives in male rabbits.

Keywords

References

[1] Benyo Z, Gille A, Kero J, Csiky M, Suchánkova MC, Nusing RM, Moers A, Pfeffer K, Offermanns S. GPR109A (PUMA-G/HM74A) mediates nicotinic acid–induced flushing. J Clin Invest. 2005;115(12):3634-3640. https://doi.org/10.1172/JCI23626.
[2] Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int J Clin Pract. 2004; 58 (7):706-713. https://doi.org/10.1111/j.1368-5031.2004.00233.x.
[3] Arfi T, Singh L, Prabhakar D, Nigamet VK. Partial Purification and Characterization of 3-Cyanopridinase responsible for Production of Nicotinic Acid. Int J Pharm Res. 2017; 8 (11): 4666-4674. https://doi.org/10.13040/IJPSR.0975-8232.8(11).4666-74.
[4] Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008; 4 (8): S20-S26. https://doi.org/10.1016/j.amjcard.2008.02.029.
[5] Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med. 2005; 258 (2): 94-114. https://doi.org/10.1111/j.1365-2796.2005.01528.
[6] Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin. 2004; 20 (8):1253-1268. https://doi.org/10.1185/030079904125004402.
[7] Barte P, Ginsberg HN. Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol. 2008; 102 (8): 1040-1045. https://doi.org/10.1016/j.amjcard.2008.05.056.
[8] Bodor E, Offermanns S. Nicotinic acid: an old drug with a promising future. Br J Pharmacol. 2008; 153: S68–S75. https://doi.org/10.1038/sj.bjp.0707528.

[9] Kamanna V, Ganji SH, Kashyap ML. The mechanism and mitigation of niacin-induced flushing. Int J Clin Pract. 2009; 63 (9): 1369-1377. https://doi.org/10.1111/j.1742-1241.2009.02099.x.
[10] Kifayatullah M, Mustafa MS, Sengupta P, Sarker MM, Das A, Das SK. Evaluation of the acute and sub-acute toxicity of the ethanolic extract of Pericampylus glaucus (Lam.) Merr. in BALB/c mice. J Acute Dis 2015;4(4):309-315. https://doi.org/10.1016/j.joad.2015.06.010.
[11] Niimi M, Chen Y, Yan H, Wang Y, Koike T, Fan J. Hyperlipidemic Rabbit Models for Anti-Atherosclerotic Drug Development. Appl Sci. 2020;10(23):8681. https://doi.org/10.3390/app10238681.
[12] Chishti KA. Synthesis of Some Nicotinic Acid Derivatives having Potential Therapeutic Activity. University of Karachi, Karachi. 2003. 58-59. https://api.semanticscholar.org/CorpusID:84033511.
[13] Cunha LF Ongaratto MA, Endres M, Barschak AG. Modelling hypercholesterolaemia in rats using high cholesterol diet. Int J Exp Pathol. 2021;102(2):74–79. https://doi.org/10.1111/iep.12387.
[14] Shah TZ, Ali AB, Jafri SA, Qazi MH. Effect of Nicotinic Acid (Vitamin B3 or Niacin) on the lipid profile of diabetic and non – diabetic rats. Pak J Med Sci. 2013;29(5):1259–1264. https://doi.org/10.12669/pjms.295.4193.
[15] Kifayatullah M, Sengupta Pinaki. Effect of Pericampylus glaucus on plasma glucose concentration and lipid profile in streptozotocin-induced diabetic rats. Bangladesh J Pharmacol. 2016; 11: 200-205. https://doi.org/10.3329/bjp.v11i1.24593.
[16] Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005; 36 (3): 232-240. https://doi.org/10.1016/j.arcmed.2005.01.005.
[17] Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 1996; 37 (5): 907-925. https://doi.org/10.1016/S0022-2275(20)42003-6.
[18] Bays H, Stein EA. Pharmacotherapy for dyslipidaemia--current therapies and future agents. Expert Opin Pharmacother. 2003; 4(11): 1901-1938. https://doi.org/10.1517/14656566.4.11.1901.
[19] Creider JC, Hegele RA, Joy TR. Niacin: another look at an underutilized lipid-lowering medication. Nat Rev Endocrinol. 2012; 8(9): 517-528. https://doi.org/10.1038/nrendo.2012.22.
[20] Trajkovska KT, Topuzovska S. High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol. Anatol J Cardiol. 2017; 18 (2): 149-154. https://doi.org/10.14744/AnatolJCardiol.2017.7608.
[21] Badimón JJ, Ibáñez B. Increasing High-Density Lipoprotein as a Therapeutic Target in Atherothrombotic Disease. Rev Esp Cardiol. 2010. 63(3): 323-333. https://doi.org/10.1016/s1885-5857(10)70065-7.

Details

Primary Language

English

Subjects

Pharmacology and Pharmaceutical Sciences (Other)

Journal Section

Research Article

Authors

Muhammad Kifayatullah ^*
0000-0003-4109-9855
Pakistan

Sudhair Abbas This is me
0009-0004-8934-2505
Pakistan

Sadaf Wadood
0009-0002-9987-5087
Pakistan

Kamran Ahmad Chishti This is me
0009-0008-5702-9409
Pakistan

Irnum Ambreen ^* This is me
0009-0004-8303-451X
Pakistan

Nisar Zamin Shah This is me
0009-0007-6611-2899
Pakistan

Haroon Badshah This is me
0000-0003-2959-0414
Pakistan

Publication Date

August 3, 2026

Submission Date

September 14, 2024

Acceptance Date

January 22, 2025

Published in Issue

Year 2026 Volume: 30 Number: 4

IZ

https://izlik.org/JA53CL96XC

Cite

RIS / Bibtex

APA

Kifayatullah, M., Abbas, S., Wadood, S., Chishti, K. A., Ambreen, I., Shah, N. Z., & Badshah, H. (2026). Synthesis and biological evaluation of nicotinic acid derivatives as anti-hyperlipidemic potential in animal model. Journal of Research in Pharmacy, 30(4), 985-992. https://izlik.org/JA53CL96XC

AMA

1.Kifayatullah M, Abbas S, Wadood S, et al. Synthesis and biological evaluation of nicotinic acid derivatives as anti-hyperlipidemic potential in animal model. J. Res. Pharm. 2026;30(4):985-992. https://izlik.org/JA53CL96XC

Chicago

Kifayatullah, Muhammad, Sudhair Abbas, Sadaf Wadood, et al. 2026. “Synthesis and Biological Evaluation of Nicotinic Acid Derivatives As Anti-Hyperlipidemic Potential in Animal Model”. Journal of Research in Pharmacy 30 (4): 985-92. https://izlik.org/JA53CL96XC.

EndNote

Kifayatullah M, Abbas S, Wadood S, Chishti KA, Ambreen I, Shah NZ, Badshah H (August 1, 2026) Synthesis and biological evaluation of nicotinic acid derivatives as anti-hyperlipidemic potential in animal model. Journal of Research in Pharmacy 30 4 985–992.

IEEE

[1]M. Kifayatullah et al., “Synthesis and biological evaluation of nicotinic acid derivatives as anti-hyperlipidemic potential in animal model”, J. Res. Pharm., vol. 30, no. 4, pp. 985–992, Aug. 2026, [Online]. Available: https://izlik.org/JA53CL96XC

ISNAD

Kifayatullah, Muhammad - Abbas, Sudhair - Wadood, Sadaf - Chishti, Kamran Ahmad - Ambreen, Irnum - Shah, Nisar Zamin - Badshah, Haroon. “Synthesis and Biological Evaluation of Nicotinic Acid Derivatives As Anti-Hyperlipidemic Potential in Animal Model”. Journal of Research in Pharmacy 30/4 (August 1, 2026): 985-992. https://izlik.org/JA53CL96XC.

JAMA

1.Kifayatullah M, Abbas S, Wadood S, Chishti KA, Ambreen I, Shah NZ, Badshah H. Synthesis and biological evaluation of nicotinic acid derivatives as anti-hyperlipidemic potential in animal model. J. Res. Pharm. 2026;30:985–992.

MLA

Kifayatullah, Muhammad, et al. “Synthesis and Biological Evaluation of Nicotinic Acid Derivatives As Anti-Hyperlipidemic Potential in Animal Model”. Journal of Research in Pharmacy, vol. 30, no. 4, Aug. 2026, pp. 985-92, https://izlik.org/JA53CL96XC.

Vancouver

1.Muhammad Kifayatullah, Sudhair Abbas, Sadaf Wadood, Kamran Ahmad Chishti, Irnum Ambreen, Nisar Zamin Shah, Haroon Badshah. Synthesis and biological evaluation of nicotinic acid derivatives as anti-hyperlipidemic potential in animal model. J. Res. Pharm. [Internet]. 2026 Aug. 1;30(4):985-92. Available from: https://izlik.org/JA53CL96XC